Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonelokimab bioequivalence study comparing prefilled syringe vs autoinjector
NCT06994936Phase 1Completed
- Sponsor
- MoonLake Immunotherapeutics
- Start
- Jun 2025
- Primary completion
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes, Nanobodies (VHH)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sonelokimab (2 arms), sponsored by MoonLake Immunotherapeutics. Primary endpoints: Area Under the Curve at 64 days, Maximum Plasma Concentration at 64 days and 1 more. Started Jun 2025; status: completed.
02
Drugs
sonelokimab
Beyond the preview
Go deeper on NCT06994936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06994936.